The hospital-based study included female outpatients who underwent HPV genotyping from 2016 through 2021. HPV prevalence followed a bimodal age distribution, reaching its highest level among participants aged 26–30 years and showing a secondary peak among those aged 61 years or older. HPV16 was the most prevalent high-risk genotype, followed by HPV52, HPV58, HPV53 and HPV51. Because the study recruited patients at one tertiary hospital, the findings characterize the women included in the clinical sample rather than establishing population-representative HPV prevalence across Northwest China.

Persistent infection was assessed in 3,542 patients who returned for follow-up. Of these, 33.75% had persistent HPV infection, with the highest persistence rate recorded among people with mixed high-risk and low-risk HPV infections. HPV positivity was correlated with elevated abnormal rates on thin-prep cytology tests, and nine high-risk HPV genotypes were significantly associated with cytological abnormalities. In the cervical cancer cases included in the analysis, HPV16 accounted for 69.7%. These findings describe statistical associations in the retrospective cohort; they do not establish that a particular HPV genotype caused an individual cervical lesion or cancer.

The study also evaluated associations between HPV infection and bacterial vaginosis, aerobic vaginitis, trichomonal vaginitis, vulvovaginal candidiasis and mixed vaginitis. HPV positivity was positively associated with bacterial vaginosis, trichomoniasis and mixed vaginitis but inversely associated with vulvovaginal candidiasis. The strength and direction of these relationships varied by HPV subtype, indicating that the results differed among viral types. The supplied findings document associations within the analyzed patients and do not show that HPV caused a vaginal disorder or that any vaginal disorder increased HPV risk. Similarly, the reported increase in the proportion of nine-valent-vaccine-covered genotypes with increasing cervical lesion severity describes the distribution of viral genotypes in the cohort, not vaccination uptake or the vaccine’s protective effect.

Subject of Research: HPV epidemiology, cervical lesions and vaginal microecological disorders among female outpatients in Shaanxi Province

Article Title: Epidemiological profile of HPV infection, associations with cervical lesions and vaginal microecological disorders, and nine-valent vaccine coverage in Northwest China: a 6-year retrospective study of 57,035 women

Article References: Li, X., Li, R., Jia, X., Wei, L., Yang, Z., Zhang, T., Li, J., Zhang, Q., Feng, H., Tan, F., Chen, Y., Zeng, L., Pan, Y., Pei, M., & Li, N. (2026). Epidemiological profile of HPV infection, associations with cervical lesions and vaginal microecological disorders, and nine-valent vaccine coverage in Northwest China: a 6-year retrospective study of 57,035 women. Virology Journal. https://doi.org/10.1186/s12985-026-03341-9

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03341-9

Keywords: human papillomavirus, HPV16, cervical lesions, persistent infection, cervical cancer, bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, nine-valent HPV vaccine, Shaanxi Province, Epidemiological, profile

The abstract states that low-risk HPV genomes remain in an episomal state while expressing E6 and E7 proteins. Compared with high-risk HPVs, these proteins have a reduced ability to degrade pRb and p53, which the review links to controlled epithelial hyperplasia rather than malignancy. It also describes activation of host signaling pathways that promote keratinocyte proliferation and wart formation, alongside innate and adaptive immune responses that can clear lesions.

Particular attention is given to the integrin–FAK–PI3K/AKT, Hippo–YAP/TAZ and MAPK–ERK pathways. The review presents these as molecular routes implicated in cutaneous benign wart formation, summarizing the existing literature on their involvement. The available evidence is limited to the published abstract and does not provide detailed methods, study populations, effect estimates or the quality assessments used to reach its conclusions.

For clinical management, the abstract identifies destructive approaches such as cryotherapy, keratolytics and excision; immunotherapies including imiquimod, interferon injections and intralesional antigen; and adjunctive approaches including photodynamic therapy and intralesional chemotherapeutics. It also discusses emerging HPV vaccination strategies. Intralesional Candida antigen and intralesional HPV vaccination are described as having encouraging clinical responses, but the review emphasizes that extensive controlled studies are needed to establish efficacy, clinical value and standardization. Because the supplied source is an abstract rather than the full review, the relative strength of evidence for individual treatments cannot be independently assessed here.

Subject of Research: Review of molecular pathways and clinical management of low-risk HPV-associated cutaneous warts

Article Title: Molecular insights and therapeutic innovations in low-risk human papillomavirus-associated cutaneous wart

Article References: Sarkar, A., Pan, S., Ghorai, T., Nayak, D., & Das, S. (2026). Molecular insights and therapeutic innovations in low-risk human papillomavirus-associated cutaneous wart. Molecular Biology Reports, 53(1), Article 1565. https://doi.org/10.1007/s11033-026-12746-2

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12746-2

Keywords: low-risk HPV, cutaneous warts, viral molecular mechanisms, keratinocyte proliferation, immune response, destructive treatment, intralesional immunotherapy, Candida antigen, HPV vaccination, clinical evidence, Molecular, insights

Researchers at the University of Liège have now confronted this question head-on in a review published in Trends in Molecular Medicine, arguing that the field’s long search for a single decisive biomarker may have been looking for the wrong kind of answer. Michael Herfs, an oncologist at the GIGA Institute in Liège, along with colleagues Diane Bruyère and Romane Geuzaine, contends that no viral, immune or molecular marker identified to date can reliably separate self-resolving infections from those destined to progress. Their analysis suggests the problem is not a shortage of candidate markers but a fundamental misunderstanding of what kind of biological system HPV-driven carcinogenesis actually is.

The core of the difficulty is that HPV-associated cancer development is not a linear process with a single molecular switch. It is a dynamic, multi-layered phenomenon in which the outcome depends on the interplay of viral characteristics, the host’s immune response, genetic and epigenetic alterations, the local microbiota, hormonal influences and broader environmental factors. On top of these interacting variables sit stochastic events, most notably the accumulation of mutations driven by virus-induced genomic instability. Two patients infected with the same viral type can follow radically different trajectories because the determinants of progression are distributed across biological scales rather than concentrated in one measurable signal.

This complexity helps explain why decades of biomarker research have produced incremental improvements rather than a decisive breakthrough. Viral load measurements, E6 and E7 oncogene expression, methylation patterns, immune cell profiling and a host of other candidate indicators have each shown promise in isolated studies, yet none has achieved the predictive accuracy needed to transform clinical decision-making. Herfs crystallizes the field’s predicament in a striking observation: perhaps the main challenge is no longer to discover a new biomarker, but to understand how all the biological mechanisms interact to determine the outcome of an HPV infection. The framing represents a conceptual shift from reductionist marker-hunting toward systems-level interpretation.

It is precisely this shift that recent technological developments have made feasible. High-throughput molecular analysis platforms can now generate vast datasets capturing gene expression, epigenetic modification, viral integration sites and immune signatures simultaneously, while artificial intelligence and machine learning approaches offer the computational tools to integrate these heterogeneous data streams into coherent predictive models. Rather than asking whether a single marker predicts progression, integrative models can weigh dozens or hundreds of features at once, potentially capturing the multi-factorial nature of carcinogenesis that has defeated simpler approaches.

The Liège team sees particular promise in using these models to distinguish between the possible trajectories of an infection or a low-grade precancerous lesion: spontaneous regression, persistence without progression, advancement to a more serious lesion, or evolution toward invasive cancer. Bruyère, a researcher at the Laboratory of Experimental Pathology, explains that artificial intelligence and integrative models could help clarify the diversity of biological trajectories observed in patients and ultimately enable a more personalised form of risk assessment. In practical terms, this would mean moving beyond the binary categorizations of current screening toward a graduated risk profile that reflects the actual biology of each individual infection.

The clinical stakes of such a capability are considerable. Current management of HPV-positive screening results and low-grade lesions relies on HPV testing, cytology and histopathological analysis, supplemented by monitoring protocols that are only weakly personalised. This one-size-fits-all approach generates a well-documented burden of unnecessary colposcopies, repeat biopsies and anxiety-inducing follow-up for patients whose infections would have resolved regardless, while simultaneously risking under-surveillance in the minority whose lesions are genuinely dangerous. A validated predictive framework could tailor follow-up intensity to actual risk, reducing overtreatment and its associated costs and harms while concentrating clinical attention where it is most needed.

However, the researchers are careful to temper expectations with an acknowledgment of the current gap between promise and practice. These new models have not yet been sufficiently validated for routine clinical use, and the path from an encouraging computational result to a deployable diagnostic involves rigorous external validation, standardization of input data, regulatory approval and demonstration of clinical utility across diverse populations. The history of biomarker research in oncology offers cautionary examples of tools that performed impressively in retrospective datasets but faltered in prospective clinical testing. The Liège authors position integrative AI approaches as the most promising avenue for improving risk stratification, not as a finished solution.

Their broader conclusion reframes the research agenda for the field. Rather than continuing to pursue the elusive single indicator that will cleanly predict progression, the future lies in a better overall understanding of the biology of HPV infections as integrated biological systems. This perspective aligns with wider trends in cancer research, where multi-omics profiling and machine learning are increasingly applied to problems whose complexity resists traditional reductionist methods. For HPV specifically, the approach could eventually unify viral genomics, host immunology, epigenetics and microbiome data into models that reflect the true determinants of infection outcome.

If that vision matures, the practical consequences could extend well beyond cervical cancer prevention. Persistent oncogenic HPV infection is also implicated in a rising proportion of oropharyngeal cancers and in anogenital malignancies, and improved risk prediction would benefit screening and surveillance strategies across all of these sites. For now, patients and clinicians must continue working with the imperfect tools of cytology, HPV genotyping and histopathology, but the Liège analysis offers a clear-eyed map of where the field must go next: away from the search for a molecular oracle and toward a genuinely integrative understanding of how viral and host biology combine to decide, infection by infection, whether the outcome is clearance or cancer.

Subject of Research: Prediction of progression risk in oncogenic human papillomavirus infection using integrative biomarkers and artificial intelligence

Article Title: Human papillomavirus: Can we finally predict which infections will progress to cancer?

Article References: Human papillomavirus: Can we finally predict which infections will progress to cancer?. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: HPV, human papillomavirus, cancer risk prediction, biomarkers, artificial intelligence, cervical cancer, carcinogenesis, risk stratification, molecular medicine, precancerous lesions, University of Liège, personalised medicine

The study, led by dermatologist Zekiye Kanat and colleagues at Inonu University School of Medicine in Malatya, drew on clinical records spanning nearly six years, from January 2020 to November 2025. The researchers identified 113 patients who had presented to the dermatology outpatient clinic and received a clinical diagnosis of verrucae, the medical term for the rough, raised lesions that human papillomavirus induces when it infects keratinocytes in the epidermis. As a comparison group, they assembled 250 age- and sex-matched healthy individuals. Matching by age and sex was a deliberate methodological choice, since both factors are known to influence wart prevalence, and any imbalance between the groups could have masqueraded as a blood group effect. Ethical approval for the retrospective design was granted by the Inonu University Health Sciences Research Ethics Committee in November 2025.

The numbers tell a straightforward story. In the patient group, the most common blood group was O, accounting for 44.2 percent of cases, while in the control group blood group A predominated at 45.6 percent. On its face, that difference might look intriguing, but statistical testing told a different tale. A chi-square comparison of the ABO distributions between the two groups yielded a p-value of 0.293, well above the conventional threshold of 0.05, meaning the observed variation was entirely compatible with random sampling noise. Rh status told the same story: positive and negative blood types were distributed almost identically between wart patients and controls, with a p-value of 0.534. Even age, the variable most carefully controlled in the design, showed no difference between the groups, with a p-value of 0.387 confirming the success of the matching procedure.

To go beyond simple comparisons, the team built a multiple logistic regression model, a statistical technique that estimates the independent contribution of each variable, blood group, Rh status, sex, and age, to the probability of having warts while holding the others constant. The results were striking in what they failed to find. No variable reached statistical significance. The closest contender was male sex, which carried an odds ratio of 1.573, suggesting that men in this cohort were somewhat more likely to have warts than women, but the p-value of 0.057 fell just short of the significance threshold. More telling still was the model’s explanatory power: a Nagelkerke R-squared of 0.033 means the entire set of variables explained barely three percent of the variation in wart occurrence. In practical terms, blood type and demographics were nearly useless for predicting who develops warts.

The clinical details of the cohort add texture to the statistical findings. Wart lesions were most commonly located on the hands, which accounted for 45.1 percent of cases, followed by the feet at 39.8 percent. That distribution is consistent with what dermatologists see in everyday practice and with the biology of transmission. Cutaneous warts spread through direct contact and through autoinoculation, and the hands and feet are the body surfaces most exposed to microtrauma, small breaks in the skin barrier that give papillomavirus particles access to the basal keratinocytes they must infect to establish a lesion. Swimming pools, communal showers, and occupational handling are classic routes of exposure, and the anatomic distribution of lesions in this study mirrors those routes rather than any immunogenetic pattern.

The null result matters because the hypothesis it tested was biologically plausible. ABO blood group antigens are carbohydrate structures synthesized by specific glycosyltransferase enzymes, and they are expressed not only on red blood cells but also on the surface of many epithelial and endothelial cells. Viruses, in turn, often rely on specific surface glycans as attachment factors or receptors. Norovirus strains, for example, bind histo-blood group antigens in the gut, which is why secretor status and blood group shape susceptibility to that virus. Helicobacter pylori exploits Lewis antigens, and some influenza strains show blood group-dependent binding patterns. A 2023 systematic review and meta-analysis published in BMC Infectious Diseases found associations between ABO type and the risk of several infections, and studies during the COVID-19 pandemic reported that group O individuals appeared at somewhat lower risk of SARS-CoV-2 infection, possibly because circulating anti-A and anti-B antibodies or differences in glycan expression modulate viral entry and immune recognition.

There is even a dermatological thread to this literature. Earlier studies have explored links between ABO blood groups and skin conditions ranging from lichen planus and pemphigoid to psoriasis vulgaris and acne severity, with mixed and often inconsistent results. One Turkish study published in 2019 examined blood groups and anogenital wart development, and researchers have also investigated blood type associations with nonmelanoma skin cancers. Recent work has added mechanistic depth: a 2024 study in Biology Research showed that H antigen expression, the glycan precursor shared by group O individuals, modulates the integrity and differentiation of epidermal keratinocytes, the very cells that papillomavirus infects. That finding made the wart hypothesis genuinely worth testing, since altered keratinocyte differentiation could theoretically change the permissiveness of the skin to viral replication.

Why, then, did no association emerge? The authors point toward the established drivers of wart pathogenesis, which operate on a different biological level. Immunosuppression is the single most powerful risk factor for cutaneous warts; transplant recipients on calcineurin inhibitors and people with advanced HIV infection can develop extensive, recalcitrant lesions, and immunodeficiency is associated with a dramatically elevated burden of HPV-related disease. Local trauma determines where lesions appear and whether inoculation succeeds. And above all, HPV genotype matters: more than 200 papillomavirus types have been described, and the alpha, beta, gamma, and mu genera infect different body sites with different clinical consequences. The interplay between a specific viral type and the local immune microenvironment of the skin likely dwarfs any subtle effect of red cell surface glycans. A retrospective design also has limits; blood group was extracted from existing records, wart diagnosis was clinical rather than HPV-genotype-confirmed, and a cohort of 113 cases may simply lack the statistical power to detect a small true effect, if one exists.

For the public, the takeaway is refreshingly simple. Knowing your blood type will not tell you whether you are likely to catch warts, and no blood group confers protection against them. Prevention still rests on the familiar pillars: avoiding direct contact with lesions, not picking or shaving over existing warts, keeping skin intact and moisturized in high-exposure settings, and seeking treatment early, since options from salicylic acid and cryotherapy to newer immunotherapies work best before lesions become large and established. For researchers, the study adds a well-designed negative result to a literature often criticized for chasing weak associations across dozens of diseases. Negative findings like this one help discipline the field, redirecting attention toward the factors that demonstrably drive infection, the virus itself, the state of the host immune system, and the microenvironment of the skin barrier. In the ongoing effort to map human genetic susceptibility to viral disease, the ABO and Rh systems, at least for cutaneous warts, can now be crossed off the list.

Subject of Research: The association between ABO/Rh blood groups and cutaneous viral warts caused by human papillomavirus

Article Title: The relationship between cutaneous viral warts and ABO/RH blood groups: a retrospective case-control study

Article References: Kanat, Z., Türkmen, D., Altunişik, N., Şener, S., Kayhan Teti̇k, B., & Güner, M. E. (2026). The relationship between cutaneous viral warts and ABO/RH blood groups: a retrospective case-control study. Archives of Dermatological Research, 318(1), Article 397. https://doi.org/10.1007/s00403-026-04858-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04858-3

Keywords: viral warts, human papillomavirus, ABO blood groups, Rh factor, dermatology, case-control study, verrucae, host susceptibility, immunosuppression, skin barrier, logistic regression, blood group antigens

The study, published in Virology Journal, examined tumor specimens from 106 Japanese patients with oropharyngeal squamous cell carcinoma, a cancer arising in the middle part of the throat that includes the tonsils and the base of the tongue. The team, led by Yumiko Hashida and Masanori Daibata of the Department of Microbiology and Infection, together with head and neck surgeons Shuichi Matsumoto and Masanori Teshima, used real-time polymerase chain reaction to screen each tumor for five viruses: human papillomavirus, cutavirus, Epstein-Barr virus, human cytomegalovirus, and Merkel cell polyomavirus. Each of these viruses has been implicated, to varying degrees and with varying strength of evidence, in human malignancies or has been found lurking in tumor tissue.

The results mapped a layered viral landscape. Across the whole cohort, HPV DNA was the most common finding, present in 47 of 106 tumors, or 44 percent. Cutavirus DNA came next, detected in 23 cases, or 22 percent, followed by Epstein-Barr virus in 21 cases, or 20 percent. Human cytomegalovirus DNA appeared in six tumors and Merkel cell polyomavirus DNA in just one. When the researchers restricted their attention to the 59 tumors that tested negative for HPV DNA, cutavirus remained the most frequently detected virus, found in 14 cases, or 24 percent, with Epstein-Barr virus in eight, human cytomegalovirus in three, and Merkel cell polyomavirus in one.

Cutavirus is a relative newcomer to virology. First identified in 2013 in stool samples from children with diarrhea, it is a small, single-stranded DNA virus belonging to the family Parvoviridae. It has since been detected in the blood of patients with cutaneous T-cell lymphoma, including mycosis fungoides, and in various tissue samples, but its role in human disease remains unsettled. Unlike HPV in cervical and oropharyngeal cancer or Merkel cell polyomavirus in Merkel cell carcinoma, cutavirus has never been established as a tumor virus. The new study does not claim otherwise; instead, it asks a narrower and more clinically grounded question: whether the mere presence of viral DNA in tumor tissue carries information about how patients fare.

To answer that question, the researchers compared viral prevalence and viral loads between HPV DNA-positive and HPV DNA-negative tumors and then tested whether any of the detected viruses correlated with clinicopathological characteristics and survival outcomes. Viral loads, measured by quantitative real-time PCR, did not differ significantly according to HPV DNA status, suggesting that the burden of these viruses in tumor tissue is broadly similar regardless of HPV status. The more striking finding emerged from the survival analyses conducted within the HPV DNA-negative subgroup.

Using Kaplan-Meier methods, the team found that patients whose HPV DNA-negative tumors harbored cutavirus DNA had significantly shorter progression-free survival, with a log-rank P value below 0.001. Progression-free survival measures the length of time after treatment during which a patient lives with no signs of cancer growth or spread, and it is often a sensitive indicator of disease behavior. Notably, the association with overall survival did not reach statistical significance, meaning that cutavirus positivity flagged a higher risk of disease progression but did not clearly translate into a measurable difference in death rates within this cohort.

The statistical case strengthened under more rigorous modeling. In univariable Cox proportional hazards regression, cutavirus DNA positivity was the only viral factor significantly associated with progression-free survival in HPV DNA-negative oropharyngeal squamous cell carcinoma, carrying a hazard ratio of 3.14 with a 95 percent confidence interval of 1.55 to 6.35 and a P value of 0.001. In practical terms, patients with cutavirus DNA in their tumors faced roughly three times the hazard of disease progression or death compared with those without it. Crucially, the association endured after the researchers adjusted for clinicopathological factors, the standard variables such as tumor extent and nodal involvement that clinicians already use to gauge risk. By contrast, Epstein-Barr virus, human cytomegalovirus, and Merkel cell polyomavirus DNA positivity showed no significant relationship with clinical outcomes in the analysis.

Why might cutavirus DNA mark more aggressive disease? The study was not designed to answer that, and the authors are careful to note that the biological significance and causal relevance of cutavirus detection remain unclear. Several interpretations are possible. The virus might play a direct role in tumor biology, perhaps by persisting in tissue and modulating the local environment, although no mechanism has been demonstrated. Alternatively, cutavirus DNA could be a passive passenger, a marker of some other characteristic of the tumor or the patient that drives the poorer outcome. It is also possible that detection reflects contamination or low-level persistence unrelated to the cancer itself. Distinguishing among these possibilities will require larger studies and mechanistic work, including efforts to demonstrate viral gene expression in tumor cells rather than mere DNA presence.

The clinical implications, if the findings hold up, could be meaningful for a patient group that currently lacks the prognostic clarity enjoyed by HPV-positive disease. HPV status is the strongest prognostic determinant in oropharyngeal squamous cell carcinoma, and the two viral categories are treated as distinct disease entities with different natural histories and treatment considerations. For HPV-negative patients, whose outlook is generally worse and whose tumors are typically linked to tobacco and alcohol exposure rather than viral transformation, additional molecular markers could help stratify risk and potentially guide the intensity of treatment or the frequency of surveillance. A simple PCR-based test for cutavirus DNA, performed on routinely archived formalin-fixed, paraffin-embedded tissue, would be technically straightforward to deploy if its prognostic value were confirmed.

The study also carries methodological caveats typical of retrospective, single-institution cohorts. The HPV DNA-negative subgroup comprised 59 patients, and the cutavirus-positive fraction within it was 14, numbers that limit statistical power and invite the possibility of confounding despite the multivariable adjustments. The authors themselves conclude that larger studies are warranted to validate the findings and clarify the significance of cutavirus DNA detection in oropharyngeal cancer. Funded by the Japan Society for the Promotion of Science and conducted with written informed consent under ethics approval from Kochi Medical School, the work exemplifies a growing trend in tumor virology: systematically screening cancer tissue for a panel of viruses rather than testing for a single suspect. Whether cutavirus ultimately proves to be a genuine player in throat cancer biology or merely a molecular bystander, the study adds a provocative data point to the ongoing effort to decode the viral ecology of human tumors and to squeeze prognostic information from the viruses that reside within them.

Subject of Research: Association of cutavirus DNA detection with prognosis in HPV-negative oropharyngeal squamous cell carcinoma

Article Title: Prognostic relevance of cutavirus DNA in human papillomavirus DNA-negative oropharyngeal squamous cell carcinoma: a retrospective cohort study

Article References: Hashida, Y., Matsumoto, S., Teshima, M., & Daibata, M. (2026). Prognostic relevance of cutavirus DNA in human papillomavirus DNA-negative oropharyngeal squamous cell carcinoma: a retrospective cohort study. Virology Journal. https://doi.org/10.1186/s12985-026-03333-9

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03333-9

Keywords: cutavirus, oropharyngeal squamous cell carcinoma, human papillomavirus, prognosis, progression-free survival, tumor virology, Epstein-Barr virus, Merkel cell polyomavirus, human cytomegalovirus, real-time PCR, head and neck cancer, retrospective cohort study

The research, published in BMC Infectious Diseases, was led by Oluwaseyi Sedowhe Ashaka of Caleb University in Lagos together with collaborators spanning Nigerian institutions including the Nigeria Centre for Disease Control and Prevention, Lagos University Teaching Hospital, the Nigerian Institute of Medical Research, and the University of Ilorin, along with partners at The University of Texas Rio Grande Valley in the United States. Recruitment took place between July 2017 and June 2018, and every participant underwent both conventional cervical cytology screening by Pap smear and molecular testing for HPV. The dual approach allowed the investigators to compare viral genotype distribution in women whose cervical cells appeared normal under the microscope with those whose smears showed abnormalities ranging from atypical squamous cells of undetermined significance to low-grade and high-grade squamous intraepithelial lesions, the cytological precursors of invasive cancer.

The molecular methodology at the heart of the study deserves particular attention because it goes beyond the detection limits of many routine screening assays. Rather than relying on a single amplification reaction, the team employed nested and multiplex polymerase chain reaction, a technique that uses two successive rounds of primer binding to boost sensitivity and then simultaneously amplifies genetic targets from eighteen distinct high-risk or probably high-risk HPV genotypes in the same reaction vessel. This nested multiplex PCR approach targeted thirteen established carcinogenic types, including the notorious HPV-16 and HPV-18, as well as five probable high-risk types such as HPV-82 and HPV-73, which are less commonly assayed in commercial test panels. The inclusion of these less-characterized genotypes proved consequential: HPV-82 was the second most prevalent type in the cohort at twenty percent, and HPV-73 ranked third at just over nine percent, figures that would likely have been missed by narrower testing strategies.

The headline genotype, HPV-35, was detected in 43.6 percent of the women tested, an extraordinarily high proportion that dwarfs the frequencies typically reported for this type in European and North American surveillance studies. HPV-35 belongs to the alpha-9 species of papillomaviruses, the same phylogenetic group as HPV-16, and it expresses the E6 and E7 oncoproteins that interfere with the p53 and retinoblastoma tumor suppressor pathways, the canonical molecular mechanism by which high-risk HPVs drive malignant transformation. Crucially, HPV-35 was the most frequent genotype across every cytological grade in the study, meaning it appeared not only in women with normal smears but also in those with progressively severe epithelial abnormalities. This pattern suggests that HPV-35 is not a benign passenger in this population but an active participant in the spectrum of cervical disease, consistent with accumulating evidence from other sub-Saharan African settings where non-16 and non-18 types carry a disproportionate share of the oncogenic burden.

Another notable finding was the frequency of mixed infections. Dual and multiple high-risk HPV infections were present in 34.5 percent of all participants, meaning roughly one in three women harbored two or more oncogenic genotypes simultaneously. Co-infection is biologically significant for several reasons. Multiple genotype infections can complicate viral competition and interference dynamics, may accelerate the progression of cervical lesions through additive or synergistic effects of different oncoproteins, and complicate genotype-specific surveillance because the presence of one dominant type can mask the detection of others depending on the assay used. In a clinical context, the high rate of multiple infections in Lagos underscores the limitations of screening algorithms designed around single-genotype detection and reinforces the case for broad-spectrum molecular panels in routine diagnostics.

The cytological findings provided an important clinical anchor for the molecular data. Abnormal cervical cytology was identified in 21.8 percent of the cohort, a substantial proportion reflecting the fact that participants were drawn from a gynecology referral clinic rather than a general population sample. Within this abnormal group, HPV-35 again emerged as the most frequent genotype across all grades of dysplasia, from low-grade squamous intraepithelial lesions to high-grade lesions. The persistence of a single non-vaccine genotype across the full cytological spectrum raises pointed questions about how well current screening and vaccination paradigms, which were largely calibrated on the epidemiology of HPV-16 and HPV-18, translate to populations where the genotype distribution is fundamentally different.

Beyond mapping the viral landscape, the study interrogated the behavioral and demographic risk factors associated with infection, using chi-square tests for initial comparisons and then multivariable logistic regression with Firth’s penalized-likelihood method to identify independent associations. This statistical approach is specifically designed for datasets in which some outcome categories contain few events, producing more reliable odds ratio estimates than standard maximum-likelihood regression when the data are sparse. Two factors emerged as independently associated with high-risk HPV infection after adjustment. A history of sexually transmitted infection nearly tripled the odds of carrying high-risk HPV, with an adjusted odds ratio of 3.27, while condom use was strongly protective, reducing the odds by more than eighty percent with an adjusted odds ratio of 0.19. Both associations were statistically robust, with confidence intervals that excluded the null value.

Equally instructive were the factors that did not retain statistical significance. Later sexual debut, defined in the study as first intercourse at age twenty-one or older, and a higher number of lifetime sexual partners both showed elevated odds ratios in the initial analysis, but these did not reach statistical significance after adjustment. Similarly, age, educational status, and marital status were not independently associated with infection once other variables were accounted for. This pattern suggests that in this Lagos cohort, the dynamics of viral transmission and clearance are shaped more directly by sexual behavior variables with clear mechanistic links to exposure, such as barrier protection and prior sexually transmitted infections indicating unprotected exposure, than by broader demographic categories. The strong protective effect of condom use aligns with the established biology of HPV transmission, which occurs through direct contact with infected epithelial surfaces, and it offers an immediately actionable target for public health messaging even in settings where vaccine coverage remains low.

The implications of the study extend well beyond Lagos. Most cervical cancer prevention programs worldwide rest on two pillars: vaccination against HPV-16 and HPV-18, the types responsible for the majority of cervical cancers globally, and cytological or molecular screening to detect precancerous lesions. The bivalent, quadrivalent, and nonavalent vaccines differ in the number of types they cover, with the nonavalent product adding HPV-31, 33, 45, 52, and 58 to the original pair, but none provides complete protection against HPV-35, HPV-73, or HPV-82. In a population where HPV-35 alone accounts for over forty percent of infections and the majority of detected genotypes fall outside even the broadest current vaccine formulation, the protective ceiling of existing immunization strategies is inherently limited. The authors argue that this mismatch makes a compelling case for region-specific vaccine development, potentially incorporating the genotypes that dominate African epidemiology, and for integrating molecular HPV genotyping into routine screening programs so that women carrying non-vaccine high-risk types are not falsely reassured.

The study also highlights the practical infrastructure needed to act on such findings. The molecular work relied on positive controls supplied by the WHO HPV LabNet laboratory for the African region at the University of Cape Town, illustrating the value of international laboratory networks in supporting genotype-level surveillance where commercial assay coverage is incomplete. With cervical cancer incidence and mortality in sub-Saharan Africa among the highest in the world, and screening coverage in many countries remaining far below the targets set by the World Health Organization’s global elimination strategy, data of this granularity are essential for calibrating local responses. The Lagos findings, derived from a carefully genotyped cohort with both normal and abnormal cytology, provide a template for the kind of evidence base that vaccine developers, screening program designers, and policymakers will need if the goal of eliminating cervical cancer as a public health problem is to be achieved on a timeline that matters for the generations of women currently at risk.

Subject of Research: Distribution of high-risk human papillomavirus genotypes and associated risk factors among women in Lagos, Nigeria

Article Title: Distribution of high-risk human papillomavirus genotypes and associated risk factors among women with normal and abnormal cervical cytology in Lagos, Nigeria

Article References: Ashaka, O. S., Omoare, A. A., Oderinde, B. S., Okunade, K. S., James, A. B., Oladiji, F., Adeniji, K. A., Agbede, O. O., Banjo, A. A. F., Aina, K. O., Rodriguez, A. A., & Roy, U. (2026). Distribution of high-risk human papillomavirus genotypes and associated risk factors among women with normal and abnormal cervical cytology in Lagos, Nigeria. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14580-0

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14580-0

Keywords: human papillomavirus, HPV-35, cervical cancer, cervical cytology, HPV genotypes, multiple HPV infections, risk factors, HPV vaccine coverage, molecular diagnostics, Nigeria, Sub-Saharan Africa, BMC Infectious Diseases

The technical approach behind these numbers is worth noting. Rather than relying on a single broad screening assay, the team used polymerase chain reaction amplification combined with flow-through hybridization, a method that allows simultaneous detection and identification of 21 distinct HPV genotypes. This matters because HPV is not one pathogen but a family of more than 200 related viruses, only some of which are classified as high-risk for cancer. Distinguishing which genotypes circulate in a given population is essential for predicting how well existing vaccines will perform and for designing regional screening programs that target the types actually present.

The five most frequently detected genotypes among the men were HPV6, HPV52, HPV16, HPV51, and HPV42. This list mixes low-risk and high-risk types: HPV6 and HPV42 are classified as low-risk, typically associated with genital warts rather than malignancy, while HPV52, HPV16, and HPV51 belong to the high-risk category linked to anogenital and oropharyngeal cancers. HPV16 is the single most carcinogenic genotype worldwide and a dominant driver of HPV-positive cancers in both sexes. The fact that it ranks among the top types in these male outpatients reinforces why vaccination and, eventually, male screening remain central to cancer prevention efforts.

One of the study’s most striking findings is the overlap between the genotypes circulating in men and those previously reported in local women in the Putian region. The predominant types in the male cohort, including low-risk HPV6 and HPV42 and high-risk HPV52, HPV51, and HPV16, substantially mirror the genotype distribution described for females in the same area. Such concordance is consistent with sexual transmission within partner networks and suggests that vaccinating or screening only one sex leaves a persistent viral reservoir in the other. The authors argue that this overlap supports including men in HPV prevention strategies and may inform future evaluation of partner-oriented prevention approaches, in which couples are considered jointly rather than in isolation.

Age emerged as a significant axis of variation. Prevalence was highest among patients older than 60 years, a pattern that contrasts with the classic bimodal age distribution often described in women, where infection peaks in young adulthood and again around midlife. In men, clearance of infection can be less efficient with age, and cumulative exposure over a lifetime may raise the probability of detectable infection in older age groups. The researchers also conducted sensitivity analyses using broader age categories, combining the 51-to-60 and over-60 groups, to confirm the robustness of the association between older age and high-risk HPV infection, indicating that the age signal was not an artifact of how the categories were drawn.

Clinical diagnosis also shaped the picture. HPV prevalence varied significantly across the six diagnostic subgroups into which patients were stratified: warts, urinary tract infections, dermatitis, genital diseases, health check-ups, and others. The warts group showed the highest infection rate at 48.7 percent, dominated by HPV6 and HPV11, the two low-risk genotypes most classically responsible for condyloma acuminatum, or genital warts. That result is biologically coherent, since patients presenting with visible warts are, by definition, already expressing an HPV-driven lesion. More unexpected was the dermatitis group, which came in a close second at 46.5 percent and displayed remarkable genotype diversity, with HPV52, HPV16, HPV42, HPV51, and HPV59 all appearing among the detected types.

The dermatitis finding carried enough statistical weight to survive multivariable regression analysis. After adjusting for other variables, dermatitis was identified as an independent risk factor for high-risk HPV infection, with the authors reporting an adjusted odds ratio and controlling for confounding using generalized variance inflation factors to check for collinearity among predictors. The biological interpretation is not settled from these data alone, but plausible mechanisms include disruption of the skin barrier providing an easier entry point for virions, local immune dysregulation reducing viral clearance, or inflammatory conditions serving as a marker for behaviors or exposures that also raise HPV risk. Whatever the direction of causality, the association suggests that dermatology clinics could represent an underused point of contact for HPV testing in men.

The vaccine analysis is where the study’s public health implications become most concrete. China’s regional vaccination programs have historically focused on girls and women, and the 9-valent HPV vaccine, which protects against genotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58, is the broadest formulation in widespread use. Yet even against this nine-type panel, the researchers calculated that 33.5 percent of HPV-positive men in the cohort carried at least one genotype not covered by the vaccine, and the coverage gap was nearly identical, at 33.9 percent, among men carrying high-risk types. In other words, roughly one third of infections, including those with cancer-associated potential, would not be prevented by the current nonavalent vaccine, a gap driven by types such as HPV51 and HPV59 that fall outside the formulation.

These coverage gaps do not diminish the case for vaccination, but they do complicate it. On one hand, the predominance of HPV6, HPV16, and HPV52 in the male cohort means the 9-valent vaccine would still address a majority of circulating infections, and HPV16 in particular is responsible for a disproportionate share of HPV-related cancers. On the other hand, the persistence of a substantial non-vaccine reservoir means that vaccination alone cannot eliminate transmission in this population, and the finding strengthens arguments for extending vaccination to boys and men, both to protect them directly against cancers and warts and to build herd protection that benefits unvaccinated partners.

The study has limitations inherent to its design. It was retrospective and drew exclusively on male outpatients at a single hospital in Putian, a prefecture-level city in Fujian Province, so the 35.2 percent prevalence cannot be generalized to the general male population, which typically shows lower rates than clinic-based cohorts. Patients visiting dermatology or urology clinics are more likely to have conditions related to or coinciding with HPV infection than men sampled at random. The ethics committee of the First Hospital of Putian City approved the study and granted an exemption from individual informed consent, and the authors declare no competing interests. Even with those caveats, the work fills a genuine gap: no previous research on male HPV prevalence in Putian had been reported, and region-specific genotype data of this kind are scarce across much of China.

The broader takeaway is that HPV epidemiology in men deserves the same granular, genotype-level attention that has long been applied to women. As vaccination programs expand and as oropharyngeal and anal cancers linked to HPV rise in many countries, understanding which types circulate in male populations, at which ages, and in association with which clinical conditions becomes essential for modeling transmission, forecasting vaccine impact, and deciding whether and when to introduce routine male screening. The Putian data, with their high prevalence, distinctive age gradient, dermatitis signal, and measurable vaccine gap, offer a template for the kind of local surveillance that global HPV control efforts will increasingly require.

Subject of Research: Prevalence and genotype distribution of human papillomavirus infection among male outpatients in Putian, Fujian Province, China

Article Title: Prevalence and genotype distribution characteristics of human papillomavirus infection among male outpatients in Putian, Fujian Province: a retrospective study

Article References: Chen, Y., Xiao, G., Chen, A., Zhang, R., & Zhang, L. (2026). Prevalence and genotype distribution characteristics of human papillomavirus infection among male outpatients in Putian, Fujian Province: a retrospective study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14565-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14565-z

Keywords: HPV, human papillomavirus, male HPV prevalence, genotype distribution, HPV vaccination, 9-valent vaccine, high-risk HPV, genital warts, dermatitis, China, epidemiology, BMC Infectious Diseases

The research team, led by Leen Ghanim of Al-Quds Bard College and Alhareth M. Amro of the Faculty of Medicine at Al-Quds University, with collaborators from Hebron University, An-Najah National University and Jordan University of Science and Technology, set out to measure three intertwined variables: knowledge of cervical cancer, attitudes toward its prevention, and self-reported screening history. Palestine is a particularly important setting for this kind of investigation because, unlike many high-income countries, it lacks an organized, population-based cervical cancer screening program. In the absence of systematic invitations, reminders and registry-based follow-up, screening depends almost entirely on women seeking it out on their own initiative or on a clinician recommending it during an unrelated visit — a model that the new data suggest is failing most of the population.

The study was conducted between November and December 2025 using an online, self-administered questionnaire adapted from a previously published knowledge, attitudes and practices instrument and modified to fit the Palestinian context. Participants answered items covering sociodemographic characteristics, cervical cancer knowledge, attitudes toward screening, and whether they had ever been screened. The scoring system was deliberately simple and transparent: each knowledge item earned one point for a correct answer and zero for an incorrect answer, a “don’t know” response or a refusal, producing a maximum knowledge score of 32. Attitude items were scored the same way, with medically appropriate responses earning one point each, for a maximum of 8. This dichotomous approach allowed the researchers to quantify both how much women knew and how favorably they viewed prevention, and then to test whether either measure predicted actual screening behavior.

The results revealed a sobering asymmetry. The mean knowledge score was 9.7 out of a possible 32, with a standard deviation of 7.2 — a figure that indicates substantial and widespread gaps in understanding of cervical cancer, its causes and its preventability. Yet the mean attitude score was 5.45 out of 8, with a standard deviation of 2.01, suggesting that most participants held generally favorable views toward cervical cancer prevention. In other words, Palestinian women in this sample were not resistant to the idea of screening; they were simply underinformed about it. The two scores were moderately correlated, meaning that women who knew more about the disease also tended to hold more favorable attitudes, but knowledge and attitudes clearly operated on different levels of the behavioral pathway.

That distinction became even more consequential when the researchers turned to multivariable logistic regression, a statistical technique that estimates the independent effect of each factor while holding all the others constant. In this analysis, four variables emerged as independently associated with self-reported previous screening: older age, marital status, higher educational level and a higher knowledge score. Notably, the attitude score was not independently associated with screening uptake once these other factors were accounted for. The implication is striking — good intentions and positive attitudes toward prevention do not translate into action unless they are anchored by concrete knowledge and by demographic circumstances that bring women into contact with the health system.

The role of age and marital status fits with what is known about how screening is delivered in settings without organized programs. Older women are more likely to have had routine gynecological encounters, pregnancies, or other healthcare interactions during which a provider might raise the topic of cervical screening, and married women similarly accumulate more contact points with reproductive health services. Education, meanwhile, shapes both health literacy and the confidence to navigate a fragmented healthcare landscape. But the strongest modifiable signal in the data is knowledge itself: women who scored higher on the 32-point knowledge scale were significantly more likely to report having been screened, which positions education as the most actionable lever available to Palestinian health authorities.

From a technical standpoint, the study’s design carries both strengths and limitations that readers should keep in mind. The cross-sectional, online format means the sample skews toward women with internet access and the inclination to complete a survey, so the true national picture could differ. Self-reported screening history is also vulnerable to recall bias and to confusion between cervical screening and other gynecological examinations, a problem that is amplified when general knowledge of what a Pap test or HPV test actually involves is low. The authors themselves frame the work as evidence-generating for health-promotion strategy rather than a definitive prevalence estimate, and the questionnaire’s adaptation from a validated instrument, along with ethics approval from Al-Quds University’s Research Ethics Committee and electronic informed consent from all participants, gives the findings a solid methodological footing within those constraints.

The public health stakes are considerable. Cervical cancer is driven overwhelmingly by persistent infection with high-risk types of human papillomavirus, and decades of evidence from countries with organized programs show that regular screening can catch precancerous lesions years before they become invasive, rendering the disease one of the most survivable cancers when detected early. The World Health Organization’s global strategy for cervical cancer elimination rests on three pillars — vaccination, screening and treatment of precancerous lesions — and countries without structured screening programs consistently report low uptake, late-stage diagnosis and preventable deaths. The Palestinian data add a granular, locally grounded data point to that global picture, quantifying exactly how wide the gap is between favorable attitudes and actual preventive behavior when no system exists to close it.

The authors’ conclusion points toward a practical remedy rooted in primary healthcare. Because higher knowledge was the key modifiable predictor of screening, they argue for health-promotion strategies embedded in primary care settings that improve cervical-cancer-specific knowledge, clarify the purpose of preventive screening — distinguishing it from examinations for symptoms — and encourage providers to recommend screening during routine healthcare encounters. Provider-led recommendation is a low-cost intervention with demonstrated effect in other low-resource settings, and it could compensate for the absence of organized invitation systems. Marital status and age, being non-modifiable, instead help identify which groups to target: outreach could prioritize younger and unmarried women who currently have the fewest natural touchpoints with screening services.

What makes this study resonate beyond Palestine is the clarity of its central lesson: attitudes are not the bottleneck. Women in the survey were broadly receptive to the idea of preventing cervical cancer, but without knowledge of why, when and how to be screened — and without a clinician or a system prompting them — that receptiveness remained dormant. For health systems across the region and in other settings without organized screening, the message is that information campaigns and provider training may deliver more screening uptake per dollar than campaigns aimed at changing opinions. As the global community pursues the WHO’s elimination targets, evidence like this underscores that the final mile of cancer prevention is often not a matter of technology or will, but of making sure every woman knows that a simple, life-saving test exists and is invited to take it.

Subject of Research: Cervical cancer screening knowledge, attitudes and uptake among women in Palestine

Article Title: Knowledge, attitudes, and factors associated with cervical cancer screening uptake among women in Palestine: a cross-sectional study

Article References: Ghanim, L., Musa, B., Massarwa, R., Mosleh, I., Manadre, S., Bari, A., Haj, N., Bozia, Y., Shqerat, H., Bakhtan, S., Alsheqerat, H., Deeb, S., & Amro, A. M. (2026). Knowledge, attitudes, and factors associated with cervical cancer screening uptake among women in Palestine: a cross-sectional study. Discover Social Science and Health. https://doi.org/10.1007/s44155-026-00458-8

Image Credits: AI Generated

DOI: 10.1007/s44155-026-00458-8

Keywords: cervical cancer, cancer screening, Palestine, women's health, human papillomavirus, health knowledge, screening uptake, cross-sectional study, cancer prevention, primary healthcare, public health, health promotion

Chaperone-mediated autophagy, or CMA, is distinct from the better-known bulk-recycling form of autophagy. Instead of engulfing entire cellular structures in membrane-bound vesicles, CMA operates one protein at a time. Cytoplasmic proteins carrying a specific pentapeptide recognition motif are bound by the chaperone HSC70 and delivered to the lysosomal membrane, where LAMP2A acts as the receptor. The substrate protein then unfolds and threads through a multimeric channel formed by LAMP2A molecules into the lysosomal lumen, where it is degraded. Because this pathway can selectively remove transcription factors, metabolic enzymes and signaling proteins, it has long been implicated in cancer progression, immune regulation and aging, yet how pathogens manipulate it has remained poorly understood.

The new work began with a proteomic search for proteins that associate with TRIM32, a member of the tripartite motif family of E3 ligases, during KSHV infection. Using mass spectrometry on purified TRIM32 complexes from infected cells, the researchers found that TRIM32 interacted prominently with components of the CMA machinery, including HSC70, HSP90 and LAMP2A itself. Gene ontology analysis of the interactors confirmed enrichment in chaperone-mediated autophagy and innate immune pathways. When cells were stimulated with double-stranded DNA, a molecular stand-in for viral DNA sensing, TRIM32 formed visible cytoplasmic bodies that co-localized with LAMP2A and other CMA components, and the physical interaction between TRIM32 and LAMP2A could be recapitulated with purified recombinant proteins in vitro.

The pivotal discovery concerned a post-translational modification known as SUMOylation, in which small ubiquitin-like modifier proteins, chiefly SUMO2 and SUMO3, are covalently attached to lysine residues on target proteins. SUMOylation is reversible and frequently alters a protein’s localization, interaction partners or stability, and it has well-documented roles in both viral infection and tumorigenesis. The team showed that TRIM32 acts as a SUMO E3 ligase for LAMP2A, conjugating SUMO2/3 to three specific lysines: K104, K132 and K289. Detailed mapping experiments revealed that K289 and K104 serve as primary sites for SUMO2 attachment, while a SUMO-interacting motif on LAMP2A, SIM1, facilitates SUMO3 modification at K132. The RING domain of TRIM32 proved essential for this modification.

What makes this modification so consequential is where it sends LAMP2A. Although LAMP2A is classically viewed as a lysosomal membrane receptor, the study found that SUMOylated LAMP2A accumulates in the nucleus during viral infection. This nuclear translocation of LAMP2A, driven by TRIM32-dependent SUMOylation, activates the CMA program, allowing the infected cell to selectively degrade a distinct set of client proteins. Among the consequences documented in the paper is the suppression of viral reactivation and inflammation: by keeping the lytic program damped down, the virus preserves latency, its long-term persistence strategy, while the altered cellular environment simultaneously favors tumor growth and the formation of new blood vessels, a process called angiogenesis.

Using KSHV as a model system, the researchers demonstrated in animal models that TRIM32-induced SUMOylation of LAMP2A promotes tumor growth and angiogenesis in vivo. When LAMP2A was depleted from KSHV-transformed cells, TRIM32’s ability to drive colony formation and xenograft expansion collapsed. Reconstituting the cells with wild-type LAMP2A restored tumorigenesis, but reconstitution with SUMOylation-defective mutants, in which the key lysines were changed to arginine, failed to do so. Immunohistochemical staining of the resulting tumors showed corresponding changes in markers of proliferation, endothelial content and viral lytic reactivation, tying the molecular modification directly to pathological outcomes.

Crucially, the mechanism appears not to be a quirk of KSHV alone. In tumor tissues from patients, the team found that TRIM32 expression positively correlates with LAMP2A in cancers associated with KSHV, Epstein–Barr virus and human papillomavirus, the viruses behind Kaposi’s sarcoma, nasopharyngeal carcinoma and cervical cancer, respectively. The correlation was stratified by the abundance of viral latent antigens such as LANA, EBNA1 and E6, suggesting that the burden of latent viral infection tracks with activation of this CMA-regulating axis. A pan-cancer analysis using the GEPIA database further showed coordinated TRIM32 and LAMP2A expression across a range of tumor types, hinting that the pathway may extend beyond classic tumor viruses.

Perhaps the most translationally exciting aspect of the study is the development of peptide inhibitors that target the SUMOylated form of LAMP2A. Derived from LAMP2A sequences, the peptides P3 and P7 were designed to disrupt the SUMOylation-dependent nuclear localization and function of the receptor. In cell culture, the peptides suppressed colony formation by KSHV-, EBV- and HPV-infected cancer cells at concentrations that showed minimal cytotoxicity toward uninfected cells. In mouse xenograft models, including both subcutaneous and intraperitoneal tumor systems, treatment with the peptides reduced tumor progression and angiogenesis. The antitumor effect depended on intact LAMP2A and SUMO2: the peptides lost efficacy in cells lacking LAMP2A or with SUMO2 knocked out, and in cells reconstituted with SUMOylation-site mutants, confirming that the drugs act precisely on the pathway the team had dissected.

The work also clarifies a long-standing puzzle about how oncogenic viruses balance two competing needs. Reactivating into the lytic cycle produces new viral particles but exposes the infection to immune detection and inflammatory stress, whereas permanent latency forgoes transmission. By activating CMA through SUMOylated LAMP2A, the virus appears to buy itself a stable middle ground: lytic genes stay quiet, inflammatory signaling is blunted, and the host cell survives long enough to accumulate the mutations and vascular support that a tumor requires. Earlier studies had shown that CMA is required for tumor growth and that LAMP2A is overexpressed in several malignancies, but the viral trigger and the specific enzymatic machinery, TRIM32 acting on defined lysines, had not previously been connected.

For patients with virus-associated cancers, the implications are significant. Current treatments for Kaposi’s sarcoma and related malignancies often rely on broad chemotherapy or immune modulation, and options specifically targeting the virus–host interface remain limited. A receptor like LAMP2A, positioned at the convergence of viral persistence and tumor maintenance, offers a single point of intervention with dual antiviral and antitumor potential. The peptide approach also demonstrates that blocking a specific post-translational modification, rather than the entire autophagy pathway, can achieve therapeutic selectivity, an important consideration given CMA’s normal roles in neurons, liver and immune cells. The authors have filed a provisional patent on the compositions and methods, and while peptide drugs face delivery and stability hurdles before clinical use, the study establishes LAMP2A SUMOylation as a promising and mechanistically well-defined target. As oncogenic viruses continue to account for a substantial share of cancers worldwide, understanding and interrupting the molecular hijacking they perform may prove one of the most consequential strategies in virology-driven cancer therapy.

Subject of Research: How oncogenic viral infection drives LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis

Article Title: Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis

Article References: Zhang, Y., Dong, Z., Chen, X., Peng, K., Huang, Q., Rao, W., Song, S., Zhang, L., Gao, S., Zhu, C., Wang, Y., Robertson, E., Yuan, Z., Wei, F., & Cai, Q. (2026). Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis. Nature Microbiology. https://doi.org/10.1038/s41564-026-02476-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02476-3

Keywords: KSHV, LAMP2A, TRIM32, SUMOylation, chaperone-mediated autophagy, oncogenic viruses, tumorigenesis, angiogenesis, Epstein-Barr virus, human papillomavirus, virus-host interactions, peptide inhibitors

Human papillomavirus is the most common sexually transmitted infection worldwide and the necessary cause of nearly all cervical cancer cases. Yet the virus is far from uniform: its genotype distribution varies markedly between countries, regions, and even cities, and those differences matter enormously for vaccination policy. Prophylactic HPV vaccines target specific subsets of genotypes, so knowing which types actually prevail in a given population determines how much protection a vaccination program can realistically deliver. Because large-scale data on genotype prevalence and viral load characteristics in the Taihu region had been lacking, the research team set out to fill that gap with a three-year survey spanning January 2023 to December 2025.

The study design was straightforward but ambitious. The investigators analyzed cervical exfoliated cell samples collected from 23,196 women who underwent HPV testing at their institution during the study window. Each sample was screened for 21 HPV genotypes using real-time fluorescence quantitative polymerase chain reaction, a technique that both identifies the viral type present and quantifies how much viral DNA is in the specimen. This dual capability allowed the team to go beyond simple positivity rates and construct viral load profiles across age groups, a dimension that many prevalence surveys omit.

The headline finding was an overall HPV infection rate of 13.20 percent, with 3,061 of the 23,196 participants testing positive. Notably, this rate remained statistically stable across the three years of the study, suggesting an entrenched and steady level of viral circulation in the region rather than a rising or falling epidemic curve. That stability provides a useful baseline against which the future impact of vaccination and screening programs can be measured.

Perhaps the most striking pattern emerged when the researchers stratified infections by age. Rather than declining monotonically with age, as some classical models of HPV epidemiology predict, prevalence followed a bimodal distribution. The highest infection rate appeared in women aged 60 and older, while the lowest rate occurred among women aged 40 to 49. This shape echoes findings from other Chinese regions and reflects a complex interplay of factors: cohort effects in lifetime exposure, changes in immune competence with age, hormonal shifts after menopause, and possibly reduced participation in screening among older women, allowing persistent infections to accumulate undetected.

The genotype ranking carried direct implications for vaccine policy. Among high-risk types, HPV52 led with a prevalence of 2.70 percent, followed by HPV58 at 1.72 percent, HPV16 at 1.35 percent, HPV39 at 1.11 percent, and HPV56 at 0.96 percent. Among low-risk genotypes, HPV53 was the most common, detected at 1.78 percent. HPV16, the single most carcinogenic type globally, ranked only third locally, while HPV52 and HPV58, types that are notably overrepresented in Asian populations relative to Western ones, dominated. This regional signature matters because the bivalent and quadrivalent vaccines, which target HPV16 and HPV18 (with the quadrivalent also covering HPV6 and HPV11), would leave a substantial fraction of local infections uncovered. The nonavalent vaccine, which adds HPV31, HPV33, HPV45, HPV52, and HPV58 to the mix, aligns far better with the genotype spectrum observed in Taihu, and the authors concluded that their data show greater theoretical concordance with the nine-valent formulation.

Age also shaped the composition of infections in ways that compound the vulnerability of older women. Women aged 60 and above exhibited significantly higher proportions of high-risk mixed infections and multiple-genotype infections compared with all other age groups. Multiple infections, in which two or more HPV types coexist in the same cervical sample, are of particular clinical interest because co-infection can complicate risk stratification and may reflect broader exposure or diminished viral clearance. The elevated burden of mixed high-risk infections in older women underscores that HPV is not simply a concern of young adulthood and that screening programs must not neglect postmenopausal populations.

The viral load analysis added a further layer of nuance. Viral load, typically measured as the quantity of viral DNA per cellular sample, is thought to correlate with infection persistence and lesion risk, although its clinical interpretation remains debated. In this cohort, the distribution of viral loads varied systematically with age. High viral loads were most frequent among women under 30, accounting for 24.29 percent of infections in that group, whereas low viral loads predominated among women aged 60 and older, making up 46.82 percent of their infections. One plausible interpretation is that younger women carry more recently acquired, actively replicating infections that are often cleared by the immune system, while older women more frequently harbor long-standing, low-level persistent infections whose cumulative cellular damage may be clinically significant despite modest viral quantities.

Taken together, the results sketch a coherent picture of HPV epidemiology in the Taihu region: a stable overall prevalence near 13 percent, a genotype hierarchy led by HPV52, HPV58, and HPV16, a bimodal age distribution peaking in the oldest women, and an age-dependent viral load architecture. The authors argue that these findings argue for region-specific prevention and control strategies rather than one-size-fits-all policies. In practical terms, that means prioritizing vaccines whose genotype coverage matches local circulating types, sustaining and possibly extending cervical screening into older age brackets, and considering viral load and multiple-infection status when triaging positive results in clinical practice.

The study also demonstrates the value of quantitative PCR-based surveillance as a public health instrument. By combining genotyping with viral load quantification across a very large sample, the Taihu dataset offers a template for other regions in China and beyond that lack local HPV epidemiology. As vaccination programs scale up globally, longitudinal studies of this kind will be essential for tracking shifts in genotype prevalence, detecting vaccine-type declines, and identifying any replacement by non-vaccine types. For now, the message from Suzhou is clear: the local viral landscape favors the broadest available vaccine coverage, and older women deserve renewed attention in the campaign against cervical cancer.

Subject of Research: Epidemiology, genotype distribution, and viral load profiles of human papillomavirus infection among women in the Taihu region of Suzhou, China

Article Title: Epidemiological characteristics, genotype distribution, and viral load profiles of human papillomavirus infection among women in the Taihu region of Suzhou: a retrospective study

Article References: Guo, J., Yan, R., & Qu, Y. (2026). Epidemiological characteristics, genotype distribution, and viral load profiles of human papillomavirus infection among women in the Taihu region of Suzhou: a retrospective study. Virology Journal. https://doi.org/10.1186/s12985-026-03301-3

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03301-3

Keywords: human papillomavirus, HPV prevalence, HPV52, HPV58, HPV16, genotype distribution, viral load, cervical cancer, nonavalent vaccine, Suzhou, retrospective study, qPCR